Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.
Jason A MouabbiWei QaioYu ShenAkshara Singareeka RaghavendraDebasish TripathyRachel M LaymanPublished in: The oncologist (2023)
In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.